Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- T +2.1%, SBGI +1.3%
Other news:
- AKRO +110.7% (reports preliminary topline results showing statistically significant reversal of compensated cirrhosis due to MASH—by both completer and ITT analyses—at Week 96 in phase 2b symmetry study)
- TVGN +37.8% (Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure)
- DADA +26.2% (announces receipt of a preliminary non-binding proposal to acquire the company)
- LGTY +23.8% (to be acquired by Aptean for $14.30 per share)
- SOR +14% (Proposes Merger With 180 Degree Capital Corp)
- IPHA +10.2% (Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors)
- ADAG +3.1% (Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA)
- AZPN +3% (Aspen Tech to be acquired by Emerson for $265.00 per share)
- RNAC +3% (received written agreement from the U.S. FDA under the Special Protocol Assessment process on the overall design of the Company's planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis)
- DEC +2.3% (enters into a definitive agreement to acquire Maverick Natural Resources, a portfolio company of EIG for total consideration of approximately $1,275 mln)
- DVAX +2% (advances board refreshment program)
- GSK +1.7% (Shingrix new prefilled syringe presentation accepted for review by EMA)
- AWK +1.5% (Pennsylvania American Water receives $19.3 mln in PENNVEST funding to make water and wastewater infrastructure improvements)
- BMY +1.5% (Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy)
- EMCG +1.3% (announces entering into a definitive merger agreement with Tianji)
- EXEL +1.2% (Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025)